Theory and strategy for Pneumococcal vaccines in the elderly

Ho Namkoong, Makoto Ishii, Yohei Funatsu, Yoshifumi Kimizuka, Kazuma Yagi, Takahiro Asami, Takanori Asakura, Shoji Suzuki, Testuro Kamo, Hiroshi Fujiwara, Sadatomo Tasaka, Tomoko Betsuyaku, Naoki Hasegawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.

Original languageEnglish
Pages (from-to)336-343
Number of pages8
JournalHuman Vaccines and Immunotherapeutics
Volume12
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Pneumococcal Vaccines
Vaccination
Pneumonia
Pneumococcal Pneumonia
Conjugate Vaccines
Adaptive Immunity
Advisory Committees
Streptococcus pneumoniae
Innate Immunity
Cost-Benefit Analysis
Cause of Death
Immunization
Epidemiology
Vaccines
Incidence
Research
13-valent pneumococcal vaccine

Keywords

  • aging
  • elderly
  • pneumococcal conjugate vaccine
  • pneumococcal diseases
  • pneumococcal polysaccharide vaccine
  • pneumococcal vaccines
  • senescence

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Theory and strategy for Pneumococcal vaccines in the elderly. / Namkoong, Ho; Ishii, Makoto; Funatsu, Yohei; Kimizuka, Yoshifumi; Yagi, Kazuma; Asami, Takahiro; Asakura, Takanori; Suzuki, Shoji; Kamo, Testuro; Fujiwara, Hiroshi; Tasaka, Sadatomo; Betsuyaku, Tomoko; Hasegawa, Naoki.

In: Human Vaccines and Immunotherapeutics, Vol. 12, No. 2, 01.02.2016, p. 336-343.

Research output: Contribution to journalArticle

Namkoong, H, Ishii, M, Funatsu, Y, Kimizuka, Y, Yagi, K, Asami, T, Asakura, T, Suzuki, S, Kamo, T, Fujiwara, H, Tasaka, S, Betsuyaku, T & Hasegawa, N 2016, 'Theory and strategy for Pneumococcal vaccines in the elderly', Human Vaccines and Immunotherapeutics, vol. 12, no. 2, pp. 336-343. https://doi.org/10.1080/21645515.2015.1075678
Namkoong, Ho ; Ishii, Makoto ; Funatsu, Yohei ; Kimizuka, Yoshifumi ; Yagi, Kazuma ; Asami, Takahiro ; Asakura, Takanori ; Suzuki, Shoji ; Kamo, Testuro ; Fujiwara, Hiroshi ; Tasaka, Sadatomo ; Betsuyaku, Tomoko ; Hasegawa, Naoki. / Theory and strategy for Pneumococcal vaccines in the elderly. In: Human Vaccines and Immunotherapeutics. 2016 ; Vol. 12, No. 2. pp. 336-343.
@article{aa6f3bb5796e454c96d9e206751e6d5b,
title = "Theory and strategy for Pneumococcal vaccines in the elderly",
abstract = "Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.",
keywords = "aging, elderly, pneumococcal conjugate vaccine, pneumococcal diseases, pneumococcal polysaccharide vaccine, pneumococcal vaccines, senescence",
author = "Ho Namkoong and Makoto Ishii and Yohei Funatsu and Yoshifumi Kimizuka and Kazuma Yagi and Takahiro Asami and Takanori Asakura and Shoji Suzuki and Testuro Kamo and Hiroshi Fujiwara and Sadatomo Tasaka and Tomoko Betsuyaku and Naoki Hasegawa",
year = "2016",
month = "2",
day = "1",
doi = "10.1080/21645515.2015.1075678",
language = "English",
volume = "12",
pages = "336--343",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Theory and strategy for Pneumococcal vaccines in the elderly

AU - Namkoong, Ho

AU - Ishii, Makoto

AU - Funatsu, Yohei

AU - Kimizuka, Yoshifumi

AU - Yagi, Kazuma

AU - Asami, Takahiro

AU - Asakura, Takanori

AU - Suzuki, Shoji

AU - Kamo, Testuro

AU - Fujiwara, Hiroshi

AU - Tasaka, Sadatomo

AU - Betsuyaku, Tomoko

AU - Hasegawa, Naoki

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.

AB - Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.

KW - aging

KW - elderly

KW - pneumococcal conjugate vaccine

KW - pneumococcal diseases

KW - pneumococcal polysaccharide vaccine

KW - pneumococcal vaccines

KW - senescence

UR - http://www.scopus.com/inward/record.url?scp=84960957895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960957895&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1075678

DO - 10.1080/21645515.2015.1075678

M3 - Article

C2 - 26406267

AN - SCOPUS:84960957895

VL - 12

SP - 336

EP - 343

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 2

ER -